Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649,...
Signet Therapeutics
Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA
China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...